Paper Citing NAMD - Abstract
Cozza, Giorgio; Venerando, Andrea; Sarno, Stefania; Pinna, Lorenzo A.
The Selectivity of CK2 Inhibitor Quinalizarin: A Reevaluation
BIOMED RESEARCH INTERNATIONAL, Art. No. 734127, 2015
Many polyphenolic compounds have been reported to inhibit protein kinases, with special reference to CK2, a pleiotropic serine/threonine kinase, implicated in neoplasia, neurodegenerative disease, and viral infections. In general however these compounds are not endowed with stringent selectivity. Among them quinalizarin (1,2,5,8-tetrahydroxyanthraquinone) turned out to be particularly potent (Ki = 0.058 mu M) and quite selective as judged by profiling it on a small panel of 70 protein kinases. Here, by profiling quinalizarin on a larger panel of 140 kinases we reach the conclusion that quinalizarin is one of the most selective inhibitors of CK2, superior to the first-in-class CK2 inhibitor, CX-4945, now in clinical trials for the treatment of cancer. Moreover here we show that quinalizarin is able to discriminate between the isolated CK2 catalytic subunit (CK2 alpha) and CK2 holoenzyme (CK2 alpha(2)beta(2)), consistent with in silico and in vitro analyses.
